Patient characteristics
Patient no. . | Age, y . | Sex . | Tumor histology . | Estrogen receptor . | Metastatic sites . | Prior surgery . | Prior treatment . |
|---|---|---|---|---|---|---|---|
| BC group | |||||||
| 1 | 38 | F | Inv ductal | Positive | Regional nodes | Mastectomy | FAC, paclitaxel, ASCT, tamoxifen, anastrozole, XRT |
| 2 | 48 | F | Inv ductal | Positive | Bone | None | AC, docetaxel |
| 3 | 50 | F | Inv lobular | Negative | Breast, lymph nodes | Mastectomy | AC, paclitaxel, vinorelbine, capecitabine, trastuzumab, XRT |
| 4 | 42 | F | Inv ductal | Positive | Bone, bone marrow | Mastectomy | AC, paclitaxel, vinorelbine, trastuzumab |
| 5 | 36 | F | Inv ductal | Positive | Bone, bone marrow | Lumpectomy | AC, CMF, paclitaxel, vinorelbine, tamoxifen, trastuzumab, XRT |
| 6 | 53 | F | Inv lobular | Positive | Bone | Lumpectomy | AC, tamoxifen, anastrozole, XRT |
| 7 | 47 | F | Inv ductal | Positive | Bone | Mastectomy | FAC, CMF, docetaxel, anastrozole gemcitabine, tamoxifen, XRT, ASCT |
| 8 | 40 | F | Inv ductal | Negative | Bone, liver | Mastectomy | FAC, docetaxel, vinorelbine, trastuzumab, XRT |
| RCC group | |||||||
| 9 | 50 | M | Clear cell | Lung, liver, spleen, lymph nodes | Nephrectomy | None | |
| 10 | 54 | M | Granular cell | Lung, liver | Nephrectomy | IL-2, IFN-α, thalidomide | |
| 11 | 45 | M | Clear/granular cell | Lung, lymph nodes | Nephrectomy | IL2, IFN-α | |
| 12 | 52 | M | Clear cell | Renal fossa | Nephrectomy | XRT | |
| 13 | 57 | M | Clear cell | Pleura, lung, | Nephrectomy | IL-2, IFN-α | |
| 14 | 49 | F | Clear cell | Lymph nodes | Nephrectomy, parotidectomy | IL-2, XRT | |
| 15 | 45 | M | Clear cell | Liver, spleen, Lymph nodes | Nephrectomy, Liver resection | IL-2, 5-FU, gemcitabine, thalidomide | |
| 16 | 53 | M | Clear cell | Lung, renal fossa | Nephrectomy | IFN-α, 5-FU, gemcitabine, cis-retinoic acid | |
| 17 | 53 | M | Clear cell | Lung, bone | Nephrectomy | IL-2, XRT | |
| 18 | 64 | M | Clear cell | Pleura, bone, skin | Nephrectomy | IFN-α, 5-FU, gemcitabine, capecitabine | |
| 19 | 57 | M | Clear cell | Lung, bone | Nephrectomy, hemipelvectomy | IL-2, IFN-α, 5-FU, gemcitabine, thalidomide, XRT | |
| 20 | 53 | F | Clear cell | Lung, lymph nodes | Nephrectomy | IL-2 | |
| 21 | 19 | F | Papillary | Lung, liver, bone | Nephrectomy | cisplatin, gemcitabine, carboplatin, ifosfamide, IL-2, IFN-α, 5-FU, thalidomide, topotecan vinblastine, capecitabine, XRT | |
| 22 | 31 | F | Clear cell | Lung, lymph nodes | Nephrectomy | IL-2, IFN-α, capecitabine | |
| 23 | 48 | M | Granular | Bone | Nephrectomy, RPLND | XRT |
Patient no. . | Age, y . | Sex . | Tumor histology . | Estrogen receptor . | Metastatic sites . | Prior surgery . | Prior treatment . |
|---|---|---|---|---|---|---|---|
| BC group | |||||||
| 1 | 38 | F | Inv ductal | Positive | Regional nodes | Mastectomy | FAC, paclitaxel, ASCT, tamoxifen, anastrozole, XRT |
| 2 | 48 | F | Inv ductal | Positive | Bone | None | AC, docetaxel |
| 3 | 50 | F | Inv lobular | Negative | Breast, lymph nodes | Mastectomy | AC, paclitaxel, vinorelbine, capecitabine, trastuzumab, XRT |
| 4 | 42 | F | Inv ductal | Positive | Bone, bone marrow | Mastectomy | AC, paclitaxel, vinorelbine, trastuzumab |
| 5 | 36 | F | Inv ductal | Positive | Bone, bone marrow | Lumpectomy | AC, CMF, paclitaxel, vinorelbine, tamoxifen, trastuzumab, XRT |
| 6 | 53 | F | Inv lobular | Positive | Bone | Lumpectomy | AC, tamoxifen, anastrozole, XRT |
| 7 | 47 | F | Inv ductal | Positive | Bone | Mastectomy | FAC, CMF, docetaxel, anastrozole gemcitabine, tamoxifen, XRT, ASCT |
| 8 | 40 | F | Inv ductal | Negative | Bone, liver | Mastectomy | FAC, docetaxel, vinorelbine, trastuzumab, XRT |
| RCC group | |||||||
| 9 | 50 | M | Clear cell | Lung, liver, spleen, lymph nodes | Nephrectomy | None | |
| 10 | 54 | M | Granular cell | Lung, liver | Nephrectomy | IL-2, IFN-α, thalidomide | |
| 11 | 45 | M | Clear/granular cell | Lung, lymph nodes | Nephrectomy | IL2, IFN-α | |
| 12 | 52 | M | Clear cell | Renal fossa | Nephrectomy | XRT | |
| 13 | 57 | M | Clear cell | Pleura, lung, | Nephrectomy | IL-2, IFN-α | |
| 14 | 49 | F | Clear cell | Lymph nodes | Nephrectomy, parotidectomy | IL-2, XRT | |
| 15 | 45 | M | Clear cell | Liver, spleen, Lymph nodes | Nephrectomy, Liver resection | IL-2, 5-FU, gemcitabine, thalidomide | |
| 16 | 53 | M | Clear cell | Lung, renal fossa | Nephrectomy | IFN-α, 5-FU, gemcitabine, cis-retinoic acid | |
| 17 | 53 | M | Clear cell | Lung, bone | Nephrectomy | IL-2, XRT | |
| 18 | 64 | M | Clear cell | Pleura, bone, skin | Nephrectomy | IFN-α, 5-FU, gemcitabine, capecitabine | |
| 19 | 57 | M | Clear cell | Lung, bone | Nephrectomy, hemipelvectomy | IL-2, IFN-α, 5-FU, gemcitabine, thalidomide, XRT | |
| 20 | 53 | F | Clear cell | Lung, lymph nodes | Nephrectomy | IL-2 | |
| 21 | 19 | F | Papillary | Lung, liver, bone | Nephrectomy | cisplatin, gemcitabine, carboplatin, ifosfamide, IL-2, IFN-α, 5-FU, thalidomide, topotecan vinblastine, capecitabine, XRT | |
| 22 | 31 | F | Clear cell | Lung, lymph nodes | Nephrectomy | IL-2, IFN-α, capecitabine | |
| 23 | 48 | M | Granular | Bone | Nephrectomy, RPLND | XRT |
Inv indicates invasive; FAC, 5-fluorouracil (5-FU), doxorubicin, and cyclophosphamide; ASCT, autologous stem cell transplantation; XRT, radiation therapy; AC, doxorubicin cyclophosphamide; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; IL-2, interleukin-2; IFN-α, interferon-α; and RPLND, retroperitoneal lymph node dissection.